Related Experiment Videos
Serotonergic manipulations in experimental neoplastic spinal cord compression
1Department of Neurology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Journal of Neurosurgery
|June 1, 1993
Summary
Serotonin receptor 5-HT2 antagonists, particularly ketanserin, show promise in treating neoplastic spinal cord compression by reducing vascular permeability and delaying paralysis in rats.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Neoplastic spinal cord compression (NSCC) causes significant neurological deficits.
- Vascular changes and prostaglandin E2 (PGE2) synthesis are implicated in NSCC pathology.
- Serotonergic pathways are altered in compressed spinal cord segments.
Purpose of the Study:
- To evaluate the effects of different serotonergic manipulation strategies on vascular permeability, PGE2 synthesis, and clinical outcomes in a rat model of NSCC.
- To investigate the role of serotonin type 2 (5-HT2) receptors in the pathophysiology of NSCC.
Main Methods:
- Rats with NSCC were treated with p-chlorophenylalanine (p-CPA) to inhibit serotonin (5-HT) synthesis, or with ketanserin or cyproheptadine to block 5-HT2 receptors.
- Vascular permeability, PGE2 synthesis, and clinical progression to paraplegia were assessed.
- Ratios of 5-hydroxyindole-3-acetic acid (5-HIAA) to 5-HT were measured to assess 5-HT utilization.
Main Results:
- p-CPA treatment reduced spinal 5-HT levels and normalized the elevated 5-HIAA:5-HT ratio.
- Ketanserin significantly reduced spinal cord vascular permeability in a dose-dependent manner.
- Cyproheptadine attenuated PGE2 synthesis, while ketanserin and p-CPA did not.
- Ketanserin, cyproheptadine, and p-CPA all delayed the onset of paraplegia, with ketanserin showing superior efficacy.
Conclusions:
- 5-HT2 receptors play a role in the vascular damage associated with NSCC, independent of PGE2 synthesis.
- Serotonergic manipulations, especially 5-HT2 receptor blockade with ketanserin, offer potential therapeutic benefits for acute NSCC treatment.
- These findings suggest a novel therapeutic avenue for managing the complications of neoplastic spinal cord compression.